Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RISE: Arexvy in the Most Elderly and Frail Population
NCT07203365Phase 3Active, not recruiting
- Start
- Aug 2025
- Primary completion
- May 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of GSK3003899A in respiratory syncytial virus infection (RSV). Started Aug 2025; status: active, not recruiting.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07203365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07203365.